Federal health agencies have restored several webpages and datasets, following a judge's order to bring back public access to information that had been removed to comply with a presidential executive ...

Discover how obesity drugs may reduce alcohol consumption alongside weight loss. Learn about this promising new research.

Prices for brand-name drugs in the U.S. are three times what the same drugs cost in other countries. And in a recent KFF survey, 3 in 10 adults reported not taking their medicine as prescribed at some ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

For decades, scientists across the globe have investigated methods to accurately measure drug permeability across the blood-brain barrier, a compact layer of cells that protect the brain from ...

This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.